Gladius Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.9M | Buy |
59,100
+3,200
| +6% | +$710K | 0.57% | 43 |
|
|
2025
Q4 | $12.8M | Buy |
55,900
+25,200
| +82% | +$5.74M | 0.7% | 32 |
|
|
2025
Q3 | $7.11M | Buy |
30,700
+22,300
| +265% | +$4.54M | 0.75% | 30 |
|
|
2025
Q2 | $1.56M | Sell |
8,400
-9,200
| -52% | -$1.71M | 0.57% | 29 |
|
|
2025
Q1 | $3.69M | Sell |
17,600
-291,100
| -94% | -$56.6M | 0.98% | 29 |
|
|
2024
Q4 | $54.9M | Buy |
308,700
+277,700
| +896% | +$51.1M | 5.89% | 4 |
|
|
2024
Q3 | $6.12M | Buy |
31,000
+13,000
| +72% | +$2.43M | 0.74% | 26 |
|
|
2024
Q2 | $3.09M | Buy |
18,000
+5,700
| +46% | +$944K | 0.38% | 26 |
|
|
2024
Q1 | $2.24M | Sell |
12,300
-9,400
| -43% | -$1.62M | 0.74% | 26 |
|
|
2023
Q4 | $3.36M | Sell |
21,700
-39,900
| -65% | -$5.82M | 0.52% | 41 |
|
|
2023
Q3 | $9.18M | Buy |
61,600
+28,600
| +87% | +$4.2M | 0.38% | 53 |
|
|
2023
Q2 | $4.45M | Sell |
33,000
-26,300
| -44% | -$3.86M | 0.22% | 50 |
|
|
2023
Q1 | $9.45M | Buy |
59,300
+47,600
| +407% | +$7.28M | 0.55% | 37 |
|
|
2022
Q4 | $1.89M | Sell |
11,700
-9,300
| -44% | -$1.43M | 0.14% | 46 |
|
|
2022
Q3 | $2.82M | Buy |
21,000
+7,300
| +53% | +$1.05M | 0.12% | 73 |
|
|
2022
Q2 | $2.1M | Buy |
13,700
+7,600
| +125% | +$1.16M | 0.11% | 68 |
|
|
2022
Q1 | $989K | Sell |
6,100
-10,200
| -63% | -$1.48M | 0.07% | 70 |
|
|
2021
Q4 | $2.21M | Hold |
16,300
| – | – | 0.18% | 56 |
|
|
2021
Q3 | $1.76M | Hold |
16,300
| – | – | 0.12% | 39 |
|
|
2021
Q2 | $1.84M | Sell |
16,300
-91,300
| -85% | -$10.3M | 0.17% | 44 |
|
|
2021
Q1 | $11.6M | Buy |
107,600
+20,300
| +23% | +$2.17M | 0.44% | 60 |
|
|
2020
Q4 | $9.36M | Buy |
87,300
+63,400
| +265% | +$6.09M | 0.46% | 65 |
|
|
2020
Q3 | $2.09M | Buy |
+23,900
| New | +$2.25M | 0.21% | 63 |
|
|
2020
Q1 | – | Sell |
-9,700
| Closed | -$859K | – | 127 |
|
|
2019
Q4 | $859K | Hold |
9,700
| – | – | 0.05% | 135 |
|
|
2019
Q3 | $735K | Hold |
9,700
| – | – | 0.03% | 169 |
|
|
2019
Q2 | $712K | Sell |
9,700
-68,200
| -88% | -$5.36M | 0.04% | 115 |
|
|
2019
Q1 | $6.28M | Sell |
77,900
-11,100
| -12% | -$908K | 0.35% | 52 |
|
|
2018
Q4 | $8.21M | Buy |
89,000
+78,400
| +740% | +$6.89M | 0.4% | 55 |
|
|
2018
Q3 | $1M | Sell |
10,600
-4,500
| -30% | -$427K | 0.1% | 42 |
|
|
2018
Q2 | $1.4K | Buy |
+15,100
| New | +$1.47M | 0.14% | 43 |
|
Other funds holding ABBV
VCM
VPM
Gladius Capital Management's ABBV Position: Q1 2026 in Review
Gladius Capital Management reduced its AbbVie (ABBV) stake by 48% in Q1 2026, selling an estimated $809K and leaving 3,925 shares worth $854K. The position accounts for 0.04% of the portfolio, ranked #96.
Gladius Capital Management first reported a position in ABBV in Q2 2018 and has held it in 26 quarters since. The position peaked at $2.53M in Q4 2018. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Gladius Capital Management held 3,925 shares of AbbVie worth $854K as of Q1 2026.
- Gladius Capital Management sold 3,647 AbbVie shares in Q1 2026, an estimated $809K.
- AbbVie made up 0.04% of Gladius Capital Management's portfolio in Q1 2026, its #96 holding.
- Gladius Capital Management first reported a position in AbbVie in Q2 2018 and has held it in 26 quarters since.
- Gladius Capital Management's AbbVie position peaked at $2.53M in Q4 2018.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Gladius Capital Management's 13F filing for Q1 2026, filed 7 May 2026.